Journal of Pathology and Translational Medicine

Seo Young Oh

2 Articles

Comparison of Analytical and Clinical Performance of HPV 9G DNA Chip, PANArray HPV Genotyping Chip, and Hybrid-Capture II Assay in Cervicovaginal Swabs: Ho Young Jung, Hye Seung Han, Hyo Bin Kim, Seo Young Oh, Sun-Joo Lee, Wook Youn Kim; J Pathol Transl Med. 2016;50(2):138-146. Published online January 13, 2016; DOI: https://doi.org/10.4132/jptm.2015.10.21

7,605 View
63 Download
4 Web of Science
3 Crossref

Background
Human papillomavirus (HPV) infection can be detected by using several molecular methods, including Hybrid-Capture II (HC2) assay and variable HPV DNA chip tests, although each method has different sensitivities and specificities. Methods: We performed HPV 9G DNA Chip (9G) and PANArray HPV Genotyping Chip (PANArray) tests on 118 cervicovaginal swabs and compared the results with HC2, cytology, histology, and direct sequencing results. Results: The overall and high-risk HPV (HR-HPV) positivity rates were 62.7% and 44.9% using 9G, and 61.0% and 30.5% using PANArray, respectively. The positivity rates for HR-HPV with these two chips were significantly lower than 55.1% when HC2 was used. The sensitivity of overall HPV positivity in detecting histologically confirmed low-grade cervical squamous intraepithelial lesions or higher was 88.7% for all three tests. The specificity was 58.5% for 9G and 61.5% for PANArray, which was significantly lower than the 72.3% for HC2. With the HR-HPV⁺ genotype threshold, the sensitivity decreased to 75.5% for 9G and 52.8% for PANArray, which was significantly lower than the 88.7% for HC2. Comparison of the two chips showed concordant results in 55.1% of the samples, compatible results in 16.9%, and discordant results in 28.0%, exhibiting poor agreement in detecting certain HPV genotypes. Compared with direct sequencing, 9G yielded no discordant results, whereas PANArray yielded 31 discordant results (26.7%). Conclusions: Compared with HC2, the HPV genotyping tests showed lower sensitivity in histologic correlation. When the two chips were compared, the 9G was more sensitive and accurate for detecting HR-HPV than the PANArray.

Citations

Citations to this article as recorded by

Concordance of Anyplex™ II HPV HR assays with reference HPV assays in cervical cancer screening: Systematic review
Habtamu Biazin
Journal of Virological Methods.2022; 301: 114435. CrossRef
The clinical performance of human papillomavirus genotyping using PANArray HPV chip: Comparison to ThinPrep cytology alone and co-testing
Jiyoung Kim, Sun-Young Jun, Lee-So Maeng
Pathology - Research and Practice.2020; 216(9): 153121. CrossRef
Analytic performance of PANArray HPV and HPV 9G DNA chip tests for genotyping of high-risk human papillomavirus in cervical ThinPrep PreservCyt samples
Jiyoung Kim, Sun-Young Jun, Magdalena Grce
PLOS ONE.2019; 14(10): e0224483. CrossRef

A Case of Multifocal Papillary Thyroid Carcinoma Consisting of One Encapsulated Follicular Variant with BRAF K601E Mutation and Three Conventional Types with BRAF V600E Mutation: Wook Youn Kim, Young Sin Ko, Tae Sook Hwang, Hye Seung Han, So Dug Lim, Wan Seop Kim, Seo Young Oh; Korean J Pathol. 2013;47(3):293-298. Published online June 25, 2013; DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.3.293

7,828 View
43 Download
7 Crossref

Abstract PDF

Multifocal papillary thyroid carcinoma (mPTC) comprises about 20-30% of PTC. In mPTC, individual tumor foci can be identical or frequently composed of different histological types including follicular, solid, tall-cell or conventional patterns. We report a case of mPTC consisting of one encapsulated follicular variant of papillary thyroid carcinoma (FVPTC) and three conventional PTCs in a 44-year-old woman. This case genetically demonstrates unique features including the simultaneous presence of the BRAF V600E (T1799A) mutation and the BRAF K601E (A1801G) mutation in conventional PTC and FVPTC, respectively.

Citations

Citations to this article as recorded by

BRAF K601E Mutation in Oncocytic Carcinoma of the Thyroid: A Case Report and Literature Review
Antonio Matrone, Fabrizia Citro, Carla Gambale, Alessandro Prete, Elisa Minaldi, Raffaele Ciampi, Teresa Ramone, Gabriele Materazzi, Liborio Torregrossa, Rossella Elisei
Journal of Clinical Medicine.2023; 12(22): 6970. CrossRef
Case of aggressive metastatic follicular variant papillary thyroid carcinoma with BRAF K601E and BCORL1 mutations
Doaa Attia, Alexander Lurie, Qihui Zhai, Robert Smallridge
BMJ Case Reports.2020; 13(6): e234208. CrossRef
BRAF gene: From human cancers to developmental syndromes
Muhammad Ramzan Manwar Hussain, Mukhtiar Baig, Hussein Sheik Ali Mohamoud, Zaheer Ulhaq, Daniel C. Hoessli, Ghaidaa Siraj Khogeer, Ranem Radwan Al-Sayed, Jumana Yousuf Al-Aama
Saudi Journal of Biological Sciences.2015; 22(4): 359. CrossRef
Clinical significance of BRAF V600E mutation in 154 patients with thyroid nodules
LINGYING YU, LIZHEN MA, QIAOFENG TU, YI ZHANG, YUEMING CHEN, DAOJUN YU, SHAOYU YANG
Oncology Letters.2015; 9(6): 2633. CrossRef
Clinicopathological Features of Rare BRAF Mutations in Korean Thyroid Cancer Patients
Uiju Cho, Woo Jin Oh, Ja Seong Bae, Sohee Lee, Young Sub Lee, Gyeong Sin Park, Youn Soo Lee, Chan Kwon Jung
Journal of Korean Medical Science.2014; 29(8): 1054. CrossRef
Recurrent Thyroid Papillary Carcinoma in Children Under Ten Years Old: Report of Two Cases and Literature Review
Byeong-Joo Noh, Ji-Youn Sung, Youn-Wha Kim, Yong-Koo Park
Korean Journal of Pathology.2014; 48(4): 297. CrossRef
Anaplastic Transformation of Papillary Thyroid Carcinoma in a Young Man: A Case Study with Immunohistochemical andBRAFAnalysis
Ji Hye Park, Hyeong Ju Kwon, Cheong Soo Park, SoonWon Hong
Korean Journal of Pathology.2014; 48(3): 234. CrossRef

Author index